Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Sorlie, 2003, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci USA, 100, 8418, 10.1073/pnas.0932692100
Yamauchi, 2001, The role of c-erbB-2 as a predictive factor in breast cancer, Breast Cancer, 8, 171, 10.1007/BF02967506
Siegel, 2012, Cancer treatment and survivorship statistics, 2012, CA Cancer J Clin, 62, 220, 10.3322/caac.21149
Mendes, 2015, The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer–a systematic review, Breast Cancer Res, 17, 140, 10.1186/s13058-015-0648-2
Rexer, 2012, Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications, Crit Rev Oncog, 17, 1, 10.1615/CritRevOncog.v17.i1.20
Finn, 2018, The dawn of vaccines for cancer prevention, Nat Rev Immunol, 18, 183, 10.1038/nri.2017.140
Mittendorf, 2016, Injecting hope–a review of breast cancer vaccines, Oncology, 30, 475
Moasser, 2007, The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis, Oncogene, 26, 6469, 10.1038/sj.onc.1210477
Castiglioni, 2006, Role of exon-16-deleted HER2 in breast carcinomas, Endocr Relat Cancer, 13, 221, 10.1677/erc.1.01047
Mitra, 2009, An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance, Mol Cancer Ther, 8, 2152, 10.1158/1535-7163.MCT-09-0295
Alajati, 2013, Mammary tumor formation and metastasis evoked by a HER2 splice variant, Cancer Res, 73, 5320, 10.1158/0008-5472.CAN-12-3186
Ursini-Siegel, 2007, Insights from transgenic mouse models of ERBB2-induced breast cancer, Nat Rev Cancer, 7, 389, 10.1038/nrc2127
Siegel, 1999, Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer, EMBO J, 18, 2149, 10.1093/emboj/18.8.2149
Kwong, 1998, A novel splice variant of HER2 with increased transformation activity, Mol Carcinog, 23, 62, 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O
Huynh, 2014, MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Delta16 mediated breast tumorigenesis and reverse trastuzumab resistance, PLoS One, 9, e114419, 10.1371/journal.pone.0114419
Tilio, 2016, Irreversible inhibition of Delta16HER2 is necessary to suppress Delta16HER2-positive breast carcinomas resistant to lapatinib, Cancer Lett, 381, 76, 10.1016/j.canlet.2016.07.028
Gabrielli, 2013, Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD), PLoS One, 8, e58358, 10.1371/journal.pone.0058358
Marchini, 2011, The human splice variant Delta16HER2 induces rapid tumor onset in a reporter transgenic mouse, PLoS One, 6, e18727, 10.1371/journal.pone.0018727
Andreani, 2017, Resveratrol fuels HER2 and ERalpha-positive breast cancer behaving as proteasome inhibitor, Aging, 9, 508, 10.18632/aging.101175
Bostrom, 2009, Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site, Science, 323, 1610, 10.1126/science.1165480
Fisher, 2010, Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine, J Mol Biol, 402, 217, 10.1016/j.jmb.2010.07.027
Bocharov, 2008, Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state, J Biol Chem, 283, 6950, 10.1074/jbc.M709202200
Red Brewer, 2009, The juxtamembrane region of the EGF receptor functions as an activation domain, Mol Cell, 34, 641, 10.1016/j.molcel.2009.04.034
Aertgeerts, 2011, Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein, J Biol Chem, 286, 18756, 10.1074/jbc.M110.206193
Uchida, 2000, Epidermal sphingomyelins are precursors for selected stratum corneum ceramides, J Lipid Res, 41, 2071, 10.1016/S0022-2275(20)32369-5
Galeazzi, 2014, Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists, J Mol Model, 20, 2120, 10.1007/s00894-014-2120-0
Fiser, 2003, ModLoop: automated modeling of loops in protein structures, Bioinformatics, 19, 2500, 10.1093/bioinformatics/btg362
Ko, 2012, GalaxyWEB server for protein structure prediction and refinement, Nucleic Acids Res, 40, W294, 10.1093/nar/gks493
Biasini, 2014, SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information, Nucleic Acids Res, W252, 10.1093/nar/gku340
Ceroni, 2006, DISULFIND: a disulfide bonding state and cysteine connectivity prediction server, Nucleic Acids Res, 34, W177, 10.1093/nar/gkl266
Jo, 2008, CHARMM-GUI: a web-based graphical user interface for CHARMM, J Comput Chem, 29, 1859, 10.1002/jcc.20945
Disis, 1998, Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ‘self’ tumour antigens, Immunology, 93, 192, 10.1046/j.1365-2567.1998.00424.x
Quaglino, 2010, A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins, Cancer Res, 70, 2604, 10.1158/0008-5472.CAN-09-2548
Reverberi, 2007, Factors affecting the antigen-antibody reaction, Blood Transfus, 5, 227
Watson, 2003, Molecular biology of the gene
Rolla, 2008, Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain, Hum Gene Ther, 19, 229, 10.1089/hum.2006.196
Betts, 2003, Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation, J Immunol Methods, 281, 65, 10.1016/S0022-1759(03)00265-5
Hori, 2003, Control of regulatory T cell development by the transcription factor Foxp3, Science, 299, 1057, 10.1126/science.1079490
Allard, 2016, CD73-adenosine: a next-generation target in immuno-oncology, Immunotherapy, 8, 145, 10.2217/imt.15.106
Wu, 2002, Phage display particles expressing tumor-specific antigens induce preventive and therapeutic anti-tumor immunity in murine p815 model, Int J Cancer, 98, 748, 10.1002/ijc.10260
Fang, 2005, The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model, Vaccine, 23, 4860, 10.1016/j.vaccine.2005.05.024
Hodyra-Stefaniak, 2015, Mammalian Host-Versus-Phage immune response determines phage fate in vivo, Sci Rep, 5, 14802, 10.1038/srep14802
Liu, 2005, Human clinical trials of plasmid DNA vaccines, Adv Genet, 55, 25, 10.1016/S0065-2660(05)55002-8
Marchini, 2013, Tailoring DNA vaccines: designing strategies against HER2-positive cancers, Front Oncol, 3, 122, 10.3389/fonc.2013.00122
Lollini, 2003, Cancer immunoprevention: tracking down persistent tumor antigens, Trends Immunol, 24, 62, 10.1016/S1471-4906(02)00030-3
Occhipinti, 2014, Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients, Clin Cancer Res, 20, 2910, 10.1158/1078-0432.CCR-13-2663
Quaglino, 2008, ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas, Curr Protoc Immunol, 10.1002/0471142735.im2009s82
Chen, 1998, DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors, Cancer Res, 58, 1965
Quaglino, 2004, Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice, Cancer Res, 64, 2858, 10.1158/0008-5472.CAN-03-2962
Cho, 2003, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, 421, 756, 10.1038/nature01392
Reilly, 2000, HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice, Cancer Res, 60, 3569
Anderson, 2002, Projection of an immunological self shadow within the thymus by the aire protein, Science, 298, 1395, 10.1126/science.1075958
Jin, 2010, CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression, Cancer Res, 70, 2245, 10.1158/0008-5472.CAN-09-3109
Meynell, 1968, Filamentous Phages specific for the I Sex Factor, Nature, 217, 1184, 10.1038/2171184a0
Gao, 2010, Phage display and its application in vaccine design, Ann Microbiol, 60, 13, 10.1007/s13213-009-0014-7
Sartorius, 2008, The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses, J Immunol, 180, 3719, 10.4049/jimmunol.180.6.3719
Grabowska, 2000, Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2, Virology, 269, 47, 10.1006/viro.2000.0185
Roehnisch, 2014, Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma, J Transl Med, 12, 119, 10.1186/1479-5876-12-119